FGFR4 As target in cancer treatment

PCT/EP2024/072737The present invention relates to the field of cancer. Concretely, the present invention provides new therapeutic approaches for the management of cancers expressing FGFR4.FGFR4 is a tyrosine kinase receptor involved in the regulation of several cellular phenotypes such as proliferation, differentiation, and survival. Imbalances in FGFR signaling have been shown to have oncogenic roles in many cancers (Turner and Grose, 2010). Interestingly, the function and kinase domain of FGFR4 differs from others FGF receptors, suggestin in may have a unique role when compared to other FGFRs (Beenken and Mohammadi, 2009). Most of the pan-FGFR inhibitors, however, fall short in their ability to competitively bind FGFR4 due to its structural dissimilarity to FGFR1-3.